Cargando…
Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
Objective: EMPEROR-Reduced and EMPEROR-Preserved studies showed the benefits of empagliflozin along with a reduction in cardiovascular death or hospitalisation for heart failure (HF). Our aim was to evaluate the economics and effectiveness of adding empagliflozin to the standard therapy for HF with...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649680/ https://www.ncbi.nlm.nih.gov/pubmed/36386229 http://dx.doi.org/10.3389/fphar.2022.1030642 |